Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1153/week)
    • Manufacturing(556/week)
    • Energy(457/week)
    • Technology(1068/week)
    • Other Manufacturing(350/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Q32 Bio

Jun 25, 2025
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Apr 30, 2025
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Mar 08, 2025
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Feb 26, 2025
Q32 Bio to Participate in Upcoming March Investor Conferences
Feb 10, 2025
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Feb 04, 2025
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Dec 10, 2024
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
Nov 07, 2024
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 14, 2024
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
Aug 29, 2024
Q32 Bio to Participate in Upcoming September Investor Conferences
Aug 08, 2024
Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 09, 2024
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
Jul 01, 2024
Q32 Bio Joins Russell 3000® Index
May 09, 2024
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 03, 2024
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
Mar 25, 2024
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Feb 21, 2024
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases

Latest News

Jul 19, 2025

MILESEEY GenePro S1 Earns MyGolfSpy's 'Most Wanted' Award, Defining New PGA-Level Precision in...

Jul 19, 2025

MILESEEY GenePro G1 Nears Successful Completion of Kickstarter Campaign with Historic 1,000-Unit Milestone

Jul 19, 2025

West Bank 'plane chalet' helps aviation dreams take off

Jul 19, 2025

Delek Logistics Partners, LP to Host Second Quarter 2025 Conference Call on August 6th

Jul 19, 2025

Delek US Holdings to Host Second Quarter 2025 Conference Call on August 6th

Jul 19, 2025

Mesa Royalty Trust Announces Trust Income for July 2025

Jul 19, 2025

Permianville Royalty Trust Announces Monthly Operational Update

Jul 19, 2025

Comfort Systems USA Announces Second Quarter 2025 Conference Call and Webcast

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia